"Empowering women worldwide to take control of their health through safe and restorative bioelectronic medicine"

About FemPulse

.....

FemPulse is dedicated to improving the quality of life for women, by providing novel wearable bioelectronic medicine as an alternative to medications.   The Company has developed a small vaginally-inserted device that uses controlled electronic pulses to regulate the dysfunctional nerves responsible for numerous medical conditions.  FemPulse’s unique wearable vaginal ring has been granted patents around the world, including in the US, Europe, and China.

The first application of the FemPulse technology platform is to treat Overactive Bladder (OAB), the bothersome sensation of  urgently needing to urinate, often resulting in increased frequency of urination and urinary incontinence.  Women must currently choose between medications, which are often ineffective and with side-effects, or invasive procedures, such as surgery to implant an effective bioelectronic device.  FemPulse’s goal is to move neuromodulation from an expensive, invasive last alternative to an affordable, accessible, and self-administered first choice of women and women’s health care providers.

You are not alone!

.....

20% of women worldwide – that’s about 1 in 5 women – live with OAB
30 million women in the U.S. alone
OAB is a highly prevalent and limiting condition worldwide

OAB represents a large, unmet medical need involving the sudden, urgent need to urinate with or without incontinence. OAB impacts a person’s freedom, work, relationships, and quality of life. Unfortunately, over 75% of patients with OAB go untreated, too many having to live with incontinence pads.  Initial treatment is generally with  medications that can have  limited efficacy, as well as potentially intolerable side-effects.  More than 9 million prescriptions are written for OAB medications each year in the U.S. alone, yet up to 80% of them are discontinued within the first year.  Female OAB in the U.S. costs the healthcare system a staggering $44.6 billion annually, 77% of which is comprised of direct medical costs, with incontinence pads alone about $2 billion.

A unique non-invasive approach to bioelectronic neuromodulation therapy (for women suffering with OAB)

The FemPulse™ Technology

State-of-the-Art Technology

FemPulse’s technology provides personalized, discreet, and affordable bioelectronic therapy for women via a vaginally inserted ring controllable by an easy-to-use remote. The first application of the self-administered vaginal ring is intended to help regulate the nerves affecting bladder function and relieve the symptoms of OAB.

Elegant and Discreet Design

The goal of the FemPulse technology is to provide women with the benefits of “set it and forget it” continuous and individualized bioelectronic treatment, altogether avoiding medications or surgical implants. The therapy is prescribed by a woman’s doctor and placed by the patient herself in the convenience of her own home, much like other vaginal devices. It features a familiar, patient-focused design with a patented technology developed by a practicing urogynecologist.

✔ Accessible
✔ Affordable
✔ Discreet
✔ Easy to Use

.....

How it Works

.....

FemPulse’s solution is designed to regulate the nerves passing between the nervous system and the bladder

OAB is a neurosensory condition in which sufferers experience an extreme sensation to urinate urgently, based on abnormal nerve signaling that is normally quiescent as the bladder fills at low volumes. When this neural pathway malfunctions, there is a false sense of fullness, resulting in a sudden and strong urge to urinate. FemPulse’s bioelectronic therapy is intended to target aberrant neural signals by sending mild electrical pulses to restore normal function, preventing urgency and its results.

Created by a woman, for women

.....

Alexandra Haessler, MD, a board-certified urogynecologic surgeon was as frustrated as her patients when it came to available treatment options for OAB. Standard of care treatment, such as behavioral modification and pelvic floor physical therapy, often left patients unsatisfied with unalleviated symptoms. Medications were often ineffective or produced intolerable side-effects, leading up to 80% of patients to abandon their first medication within a year. Third-line therapies were more invasive, expensive, and difficult to access, requiring a specialist. While implanted neuromodulation surgery worked well, the invasiveness and high cost of a surgical procedure made it a viable option for only a few in the US and even fewer abroad. Dr. Haessler kept waiting for advances in technology to provide women with a vaginal insertable device, rather than surgically-implanted neuromodulation. When a wearable bioelectronic device never arrived, she took it upon herself to develop this novel and patient-friendly treatment. Her deep knowledge of the science combined with her understanding of women’s treatment goals enabled her to develop this convenient approach to treating the source of the issue. Dr. Haessler patented the design and started FemPulse to develop and clinically demonstrate the safety and efficacy of the device.

Latest News

. . . . .

FemPulse Ring Gains CE Mark Certification for the EU

FemPulse™, a bioelectronic  medical technology company with first application overactive bladder (OAB), announced today that the Company’s FemPulse Ring™ has been granted CE Mark certification for the European Union and is now listed in the European Database on Medical Devices (EUDAMED). 

Read More

FemPulse Clinical Data to be Presented at ICS on October 9, 2026

FemPulse, a bioelectronic  medical technology company with first application overactive bladder (OAB), announced today that data from two recent clinical studies will be presented at the International Continence Society (ICS) annual meeting in Maastricht, The Netherland on October 9, 2026. 

Read More